NCT03535194.

Study name	A study to assess if mirikizumab is effective and safe compared to secukinumab and placebo in moderate‐to‐severe plaque psoriasis (OASIS‐2)
Methods	RCT, active/placebo‐controlled, double‐blind study Date of study: May 2018 Location: world‐wide Phase 3
Participants	Randomised: 1484 participants Inclusion criteria Participant must have chronic plaque psoriasis for at least 6 months Exclusion criteria Not be breastfeeding or nursing woman Must not have had serious, opportunistic, or chronic/recurring infection within 3 months Must not have received a Bacillus Calmette‐Guerin (BCG) vaccination within 12 months or received live vaccine(s) (including attenuated live vaccines) within 12 weeks of baseline or intend to receive either during the study Must not have any other skin conditions (excluding psoriasis) Must not have previous exposure to Cosentyx and any other biologic therapy targeting IL‐17 (including Taltz) Must not have received anti‐tumour necrosis factor (TNF) biologics within 8 weeks Must not have previous exposure to any biologic therapy targeting IL‐23 (including Stelara)
Interventions	Intervention A. Mirikizumab Control interventions B. Secukinumab C. Placebo
Outcomes	At week 16 Primary composite outcome PASI 90 ‐ IGA 0/1 Secondary outcome PASI 75 DLQI SF‐36 Change from baseline in quick inventory of depressive symptomology
Starting date	Study start date: May 2018 Actual study completion date: May 2020 Last update posted: August 2020, active, recruiting
Contact information	Study Director: call 1‐877‐CTLILLY (1‐877‐285‐4559)
Notes	Sponsor: Eli Lilly and Company Ongoing study Last checked in September 2020